|
|
|
 |
 |
|
|
Dowpharmasm Awards Prize Lecture for Creativity in Chiral Chemistry Midland, MI - July 02, 2007 Dowpharmasm, a business unit of The Dow Chemical Company, has awarded Professor Michael J. Krische, University of Texas at Austin, the Dowpharma Prize Lecture for Creativity in Chiral Chemistry. As part of the award, Krische will present his work, “Formation of C-C Bonds via Catalytic Hydrogenation” at Modern Synthetic Methods and Chiral USA on July 11 in Philadelphia, Pa. The Dowpharma Prize Lecture recognizes innovative work in the field of asymmetric synthesis by a young North American academic. Krische was acknowledged for developing a new technology that involves asymmetric C-C bond formation via catalytic hydrogenation. “This is a remarkable discovery, and we are pleased to provide Professor Krische with the opportunity to present his work to scientists and professionals in the pharmaceutical and fine chemical industries at Modern Synthetic Methods & Chiral USA,” stated Dr. Mark Cassidy, business director Small Molecules, Dowpharma. “When developed further, this technology could allow chemists to use inexpensive feedstocks, such as acetylene and styrene, to manufacture more complex chiral molecules.” The formation of C-C bonds is a fundamental step in the manufacture of chemical products, including pharmaceuticals. Krische has discovered a new method of forming these bonds by reacting transient rhodium species with carbonyl compounds and imines, thus adding a new dimension to catalytic hydrogenation. A member of the independent judging panel commented, “Krische’s work is a true paradigm shift that I believe will have far-reaching consequences in the synthesis of complicated molecules.” Krische is the second to receive the Dowpharmasm Prize Lecture award. Professor Matthew Gaunt, Cambridge University was awarded for his work involving a new catalytic technology for chemical synthesis at Chiral Europe in 2005. About Dowpharmasm Dowpharmasm contract manufacturing services provides the pharmaceutical and biopharmaceutical industries with innovative technologies, products and services for clients in drug discovery, development, manufacturing and delivery. Dowpharma offers process development, route selection, methods development, chiral capabilities and associated analytical services as well as manufacturing and scale-up from feasibility, through clinical trials, to commercial launch. Dowpharma currently manufacturessm all molecule APIs and intermediates, catalysts, cGMP polymers, and poly(ethylene) glycols (PEGs) and provides technology for protein expression through microbial fermentation. For more information on Dowpharma visit www.dowpharma.com. About Dow
For Editorial Information: Michael Altmann Urszula Murphy |
||
|
Dow Home Privacy Statement Internet Disclaimer Accessibility Statement Site Map Copyright © The Dow Chemical Company (1995-2008). All Rights Reserved. 
|
||